NCT00525330 - A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Type 2 Diabetes

Interventions

DRUG

KRP-104 QD Drug: Placebo Drug: Metformin

KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal

DRUG

Placebo Drug: Metformin

Two tablets 15 to 30 minutes before each meal, morning and evening.

DRUG

KRP-104 BID Drug: Placebo Drug: Metformin

KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.

Trial Locations (1)

Unknown

San Diego